No affiliate links appear in this article. Informational only, not medical advice.
Vanity Board currently indexes 1,631 products. An ingredient-first, evidence-weighted method helps organize that catalog more intelligently than a list based only on star ratings or launch noise. It can identify products that deserve a closer look, group formulas by intended function, and expose where marketing language outruns the available evidence.
But an ingredient list is not the finished product. Responsible rankings need to preserve that distinction.
What an ingredient list can show
In the United States, cosmetic ingredients generally appear in descending order of predominance. FDA rules allow ingredients at one percent or less to appear in any order after ingredients above one percent, and color additives have separate ordering flexibility. That means list position can sometimes offer context, but it does not reveal a precise concentration for most ingredients.
A catalog can still use ingredient information to flag broad functional groups, compare fragrance declarations, identify known allergens for further review, or find formulas containing an ingredient supported by credible research. It can also make routine search more efficient by separating cleanser, leave-on treatment, moisturizer, mask, and sunscreen formats.
What the list cannot prove
It cannot tell us the exact concentration of most ingredients, the grade of a raw material, the stability of the formula, the delivery system, the sensory finish, the packaging interaction, or how a particular person will respond. Two formulas with similar lists can perform very differently. A familiar ingredient near the top of a list may strengthen a hypothesis, but it is not a substitute for finished-product evidence.
Evidence weighting needs levels
Vanity Board should label the kind of support behind each conclusion. One practical hierarchy is: finished-product testing and regulator-recognized evidence first, then high-quality research relevant to the ingredient and use, followed by credible manufacturer documentation, and finally editorial or consumer observations. The lower levels can add context, but they should not be written as if they carry the certainty of the higher ones.
Claims must stay inside the cosmetic lane
FDA explains that cosmetics and drugs are defined in part by intended use. Claims about treating or preventing disease, or affecting the structure or function of the body, can move a product into drug territory. An editorial system repeating a brand’s language should therefore screen for therapeutic phrasing rather than amplify it automatically.
Our working rule
Ingredient evidence can raise or lower confidence in a product’s fit for a question. It should not generate an absolute promise. The published output should state what the system knows, what it inferred, and what still requires testing. That is slower than turning every ingredient match into a recommendation, but it is far more useful.